Basic Information
| LncRNA/CircRNA Name | THOR |
| Synonyms | Lnc-THOR, ENSG00000226856 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, in vitro knockdown etc. |
| Sample | osteosarcoma tissues, cell lines (U2OS, MG-63 and SaOs-2) |
| Expression Pattern | down-regulated |
| Function Description | In the current study, we show that Lnc-THOR is expressed in established and primary human OS cells. It is also detected in human OS tissues, but not in the surrounding normal bone tissues. siRNA-induced knockdown or CRSIPR/Cas9-mediated knockout Lnc-THOR significantly inhibited human OS cell survival and proliferation. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) target mRNAs, including IGF2, GLI1 and CD44, were downregulated in Lnc-THOR-silenced OS cells as well. Conversely, forced over-expression of Lnc-THOR enhanced IGF2BP1 target mRNA expression, promoting OS cell survival and proliferation. In vivo, xenograft tumors of Lnc-THOR-knockout U2OS cells grew significantly slower than the control U2OS tumors. |
| Pubmed ID | 29626476 |
| Year | 2018 |
| Title | Long non-coding RNA THOR promotes human osteosarcoma cell growth in-vitro and in-vivo. |
External Links
| Links for THOR | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |